Secondary Logo

Journal Logo


Safety of intravenous iron use in chronic kidney disease

Kalra, Philip A.; Bhandari, Sunil

Author Information
Current Opinion in Nephrology and Hypertension: November 2016 - Volume 25 - Issue 6 - p 529-535
doi: 10.1097/MNH.0000000000000263
  • Open



Iron deficiency anaemia (IDA) is a major health problem worldwide and it is commonly associated with chronic diseases such as chronic kidney disease (CKD) [1]. IDA is associated with fatigue, reduced quality of life, progression of disease, and poorer clinical outcomes [1–3]. Oral iron preparations may not be adequate for use in all patients because of intolerance, impaired absorption because of inflammation, and large iron deficits [4]. Therefore, intravenous (i.v.) iron is being increasingly used in patients not responding to oral iron. Moreover, some international guidelines recommend i.v. iron as the preferred option in the treatment of IDA in circumstances where there is decreased transport capacity and a high iron demand, as it is more effective and better tolerated than oral iron [5–7]. Currently, ferric carboxymaltose (Ferinject/Injectafer; Vifor Pharma, Zurich, Switzerland), ferric gluconate (Ferrlecit; Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA), ferumoxytol (Feraheme; AMAG Pharmaceuticals, Inc., Waltham, MA, USA), high molecular weight (HMW) iron dextran (Dexiron/Dexferrum; Luitpold Pharmaceuticals, Shirley, NY, USA), low molecular weight iron dextran (Cosmofer/Infed; Pharmacosmos A/S, Holbaek, Denmark), iron isomaltoside (Monofer; Pharmacosmos A/S), and iron sucrose (Venofer; Vifor Pharma) are available for use in clinical practice. All are considered efficacious in equivalent doses for treating anaemia, but they differ in their dose ranges, the duration and frequency of administration, and in their safety profiles.

Owing to the potential risk of anaphylactic reactions with the use of HMW iron dextran, some clinicians express concern about using i.v. iron for the treatment of IDA. Second-generation i.v. iron formulations, such as ferric gluconate and iron sucrose, have a lower frequency of anaphylactic reactions, and they became widespread in the treatment of IDA. However, large-dose administration is not possible with these agents and a typical iron deficit of 1000–2000 mg would require several visits. The introduction of the third-generation i.v. irons, ferric carboxymaltose and iron isomaltoside, resolved this limitation. In this review, we assess the safety of using i.v. iron, with particular focus on patients with CKD.

Box 1
Box 1:
no caption available


A literature search was conducted in May 2016 that covered the i.v. iron literature published since January 2015. Information was obtained from PubMed using the keywords ‘intravenous’ and ‘iron’ in the title/abstract. A total of 365 articles were identified, of which 37 were considered relevant to the topic. These articles were studied, and the most significant or novel are referred to in the current review. In addition, 36 important references are included, which were either published before January 2015 or not included in the PubMed database, for example, regulatory documents, guidelines, and the Standardised Medical Dictionary for Regulatory Activities (MedDRA) homepage.


Hypersensitivity (including anaphylactic) reactions

It is well recognized that many medications can cause an allergic reaction and potential anaphylaxis [8]. HMW iron dextran has been associated with an increased risk of anaphylaxis, whereas these reactions are rarely observed with the more novel irons [9–14]. Wang et al.[15▪▪] compared the relative risk (RR) of anaphylaxis among i.v. iron dextran, ferric gluconate, iron sucrose, and ferumoxytol. The analysis included retrospective cohort studies of i.v. iron administered to iron-naïve patients (n = 688 183) registered in the US fee-for-service Medicare program (January 2003 to December 2013). The first exposure risk for anaphylaxis was 68/100 000 persons [95% confidence interval (CI): 57.8–78.7] for iron dextran and 24/100 000 persons (95% CI: 20.0–29.5) for the other three nondextran i.v. iron products combined with an adjusted odds ratio of 2.6 (95% CI: 2.0–3.3; P < 0.001). Hence, the risk of one ‘anaphylaxis’ event appeared to occur in every 1500–4000 infusions. However, there are several methodological issues with this study, as discussed by DeLoughery and Auerbach [16▪▪]. The authors did not distinguish between HMW and low molecular weight iron dextrans and the diagnosis of anaphylaxis was derived from an algorithm based on International Classification of Diseases, Ninth Revision codes; one of the criteria was a combination of codes for allergies, symptoms, and treatments such as the administration of diphenhydramine and steroids. The algorithm allowed a patient to be classified as having ‘anaphylaxis’ simply by having received a premedication, rather than having definite evidence of a hypersensitivity reaction. No case note review to verify the nature of the ‘anaphylactic’ events was undertaken and the authors did not comment on mortality related to anaphylaxis. However, mortality data could be derived from the supplemental data provided. Fatal reactions on the day of iron administration for the period 2003–2013 were far lower, occurring between once every 12 500 and 25 000 infusions, with fatalities being greater with the other three irons compared with iron dextran (RR: 2.07, 95% CI: 0.99–4.78, P = 0.04).

Nature of intravenous iron reactions

A major problem is that many i.v. iron reactions are incorrectly classed as anaphylaxis. The classical definition of anaphylaxis is a serious, potentially life-threatening allergic reaction that typically develops quickly (minutes to a few hours) and may cause death because of circulatory collapse or bronchospasm, and usually requires immediate treatment. However, there are other more frequent reactions, such as labile iron reactions and the ‘Fishbane’ reaction, that might be mistakenly reported as anaphylaxis reactions [17]. The retrospective identification of anaphylaxis is therefore difficult and clinicians define the term differently and there is no consensus on what to report and when. Therefore, the use of hard clinical endpoints, such as fatalities, appears to be the most undisputable outcome measure.

Although adverse events occur with i.v. iron, the frequency of serious adverse drug reactions (ADRs, related adverse events) in prospective trials is very low and impossible to investigate comparatively in randomized controlled trials (RCTs). Furthermore, the majority of RCT have only a short follow-up period (and drug exposure) and are inadequate to assess the long-term safety and mortality risk [18]. Instead postmarketing reporting of such events could be used to estimate the frequencies [11,12]. Postmarketing safety data are, however, inherently unreliable as they are subject to numerous biases. As mentioned above, identification of anaphylaxis is difficult and clinicians define the term differently. An algorithm outlining grading and management of acute hypersensitivity reactions to i.v. iron infusions can be found in the review by Rampton et al.[19] and recent studies by Szebeni et al.[20] and Macdougall et al.[21], the latter summarized in a document published after a Kidney Disease: Improving Global Outcomes (KDIGO) expert conference on iron controversies.

Another method to standardize the definition of anaphylactic reactions is to use the MedDRA Queries (SMQs) applied in pivotal regulatory trials in the United States. SMQs are validated, standard sets of MedDRA terms, which have undergone extensive review, testing, analysis, and expert discussion by a working group of MedDRA and product safety experts [22]. The SMQs for anaphylactic reaction include hypersensitivity/allergic reactions and any serious or severe treatment-emergent adverse event occurring on the day of or the day after dosing. The SMQs for anaphylactic groups of specific terms can be found in Table 1. Use of such standardized terms in the setting of rigorously conducted prospective Good Clinical Practice trials for regulatory approval are likely to avoid many of the biases with retrospective studies such as the above study by Wang et al.[15▪▪]. In general, the modern i.v. irons have very low frequencies of severe and serious hypersensitivity reactions (Table 2).

Table 1
Table 1:
Regulatory standardized Medical Dictionary for Regulatory Activities Queries terms for the definition of hypersensitivity events
Table 2
Table 2:
Serious or severe hypersensitivity events on day or day after a dosing with intravenous iron, based upon Medical Dictionary for Regulatory Activities Queries terms for anaphylactic reactions

Risk of infection

It has been postulated that i.v. iron might promote infection [24] but there are conflicting studies in the literature. The risk of infection is thought partly to be because of some i.v. irons having a potentially immunoactivating effect; for example, less stable i.v. irons, such as iron sucrose, induce phenotypical and functional monocytic alterations [25], and have a higher potential to modulate monocyte differentiation to macrophages and mature dendritic cells than more stable preparations [26]. A few small trials in CKD populations suggest an increased infection risk with i.v. iron [27,28▪▪]. Agarwal et al.[28▪▪] undertook a single-centre RCT that randomly assigned nondialysis-dependent CKD (NDD-CKD) patients with IDA to either oral iron (69 patients) or i.v. iron sucrose (67 patients); the primary endpoint examined whether i.v. iron influenced the rate of loss of renal function with time. As a secondary outcome measure, they found an increase in serious adverse events (SAEs) because of infections in patients receiving i.v. iron, with infections in the oral iron group occurring 27 times in 11 patients, whereas in the i.v. iron group, they occurred 37 times in 19 patients; the adjusted RR ratio was 2.12 (1.24–3.64), P < 0.006 [28▪▪]. Litton et al.[29] published a systematic review and meta-analysis of RCT to investigate the safety and efficacy of i.v. iron therapy. They obtained data from Medline, Embase, and the Cochrane Central Register of Controlled Trials from 1966 to June 2013. In total, 72 trials with 10 605 patients were included. Intravenous iron was found to be associated with a significant increase in RR of infection of 1.33 (95% CI: 1.10–1.64) compared with oral or no iron supplementation [29]. However, these findings were subject to bias as infection was not a predefined endpoint in many of the trials that were included in the meta-analysis. They could also not detect a dose–response association between iron and risk of infection, further undermining the causal relationship [30]; and these limitations were acknowledged by the authors.

Other studies have shown contrasting results regarding risk of infections associated with i.v. iron [31–33]. In another meta-analysis that included 103 RCT, Avni et al.[34▪] concluded that there was no increased risk of infections with the use of i.v. irons. Ishida et al.[35▪] published a retrospective observational cohort study using data from the US Renal Data System examining 22 820 adult Medicare beneficiaries receiving in-centre haemodialysis, who had been hospitalized for bacterial infection in 2010; 2463 (10.8%) had received i.v. iron in the 14 days preceding their hospitalization. Patients treated with i.v. iron did not have a higher 30-day mortality (odds ratio 0.86) or readmission rate for infection within 30 days of discharge, compared with patients not receiving i.v. iron.

Risk of direct cellular damage and cardiovascular events

Another concern is that i.v. iron might cause endothelial damage and promote atherosclerosis by generating oxidative stress [34▪] with potential consequences of long-term cardiovascular toxicity. Intravenous iron has been shown to induce oxidative stress [36] as labile iron is able to generate highly reactive hydroxyl radicals by reacting with hydrogen peroxide in the Fenton reaction [37]. This is supported by a small study by Agarwal et al.[38] showing that iron sucrose induces oxidative stress associated with transient proteinuria and tubular damage in CKD patients. The direct toxic effect of iron on renal tubular cells appears greatest with iron sucrose and less with iron dextran and iron isomaltoside [39].

The single-centre RCT conducted by Agarwal et al.[28▪▪] has already been alluded to in the context of infection risk. However, that study of 136 NDD-CKD patients was halted early based on futility of the primary endpoint (failure to demonstrate differences in CKD progression) and because the RR of serious cardiovascular events was 2.51 for patients treated with i.v. iron. Cardiovascular events were nominally higher with i.v. iron but the number of patients developing these events was almost identical (there were 55 events in 17 patients treated with i.v. iron and 36 in 19 patients who received oral iron; P = 0.033).

These findings are inconsistent with the results of larger randomized trials [32,40▪] and we therefore feel that they should be interpreted with caution and warrant further study.

Other unwanted effects of intravenous iron

Intravenous irons differ in their capability to induce medically significant hypophosphatemia [41]. This has been reported most often with ferric carboxymaltose [42] arguing against a class effect; the mechanism is substance specific via an increase in fibroblast growth factor 23 [43,44]. This area requires further study to clarify the significance of these variable effects of i.v. iron preparations.


Kalra et al.[40▪] published a RCT conducted in 351 iron-deficient NDD-CKD patients receiving either iron isomaltoside or oral iron. ADRs were observed in 10.5 and 10.3% of the patients in the i.v. and oral iron groups, respectively. Three serious ADRs (two events of hypersensitivity in the i.v. iron group and one event of oesophagitis in the oral iron group) were reported. All patients fully recovered from the events. There were three fatal events in the i.v. iron group but none was drug related. All three patients had a significant prior history of cardiac disease; two elderly patients had decompensated heart failure for 6 weeks and 3 months, respectively, after i.v. iron, the other had pneumonia complicated by myocardial infarction. More patients treated with oral iron were withdrawn from the trial because of adverse events (4.3%) than patients treated with i.v. iron (0.9%) [40▪]. In a larger RCT of iron-deficient NDD-CKD patients, Macdougall et al.[32] randomized 626 patients to either i.v. ferric carboxymaltose or oral iron. Approximately, 15 and 29% of the reported adverse events were considered treatment related in the ferric carboxymaltose and oral iron groups, respectively. Two patients in the ferric carboxymaltose group experienced a drug hypersensitivity reaction, one of which was graded mild and the other graded moderate in severity. Both patients fully recovered. One serious ADR was observed in the oral iron group. Adverse events leading to discontinuation occurred in approximately 4 and 13.5% of the patients in the ferric carboxymaltose and oral iron groups, respectively. In total, 25 patients died during the trial (10 in the ferric carboxymaltose group and 15 in the oral iron group) but none of the events was assessed as related to the trial drug [32].

Bhandari et al.[45▪] published a RCT conducted in 351 haemodialysis patients receiving either iron isomaltoside or iron sucrose. ADR were observed in 5.2 and 2.6% of the patients in the iron isomaltoside and iron sucrose groups, respectively. Three of these ADR were reported as serious; one was because of hypersensitivity in the iron isomaltoside group and there were ADR of staphylococcal bacteraemia and dyspnoea in the iron sucrose group. Three patients in the iron isomaltoside group died during the trial and an additional two patients died without being exposed to trial drug. In all cases, these events were deemed not related to the trial drug and the observed mortality was in line with the expected mortality in this population during the time frame of the RCT [45▪]. The meta-analysis by Avni et al.[34▪] has already been alluded to. In RCT (1965–2013) in which i.v. iron was trialled against a comparator agent, placebo, or no therapy, a total of 10 390 patients were treated with i.v. iron compared with 4044 patients treated with oral iron, 1329 with no iron, 3335 with placebo, and 155 with intramuscular iron. No increased risk of SAEs with i.v. iron was detectable in this analysis (RR, 1.04; 95% CI: 0.93–1.17) [34▪].


Owing to the relatively high risk of anaphylactic reactions observed with the historic i.v. irons, there has been some reluctance in the use of i.v. irons, and recent studies have suggested continued risk. However, investigating the frequencies of ADRs, especially anaphylactic reactions, is difficult as clinicians define the term differently and it is well recognized that milder reactions, which are usually self-limiting, may be misclassified as anaphylactic reactions. Using fatalities or SMQ terms as outcome measures might help in this matter as well as the algorithms provided by the KDIGO expert group (Macdougall et al.[21]), Rampton et al.[19], and Szebeni et al.[20]. Nonetheless, there is no doubt that the HMW iron dextrans are associated with increased risks, and therefore, these i.v. irons should be avoided [9–14].

The second and third-generation i.v. irons are considered equally efficacious in treating iron deficiency in equivalent doses but they differ in their stability [46], ability to induce oxidative stress [36–38], their effect on immune function [25,26], and dosing and administration options [47]. Iron isomaltoside seems to have a lower frequency of serious and severe hypersensitivity reactions, when using a novel approach of prospectively reported standardized medical terms pooled from different randomized trials. This is a promising approach for future research into the risk of serious hypersensitivity. In conclusion, with the exception of HMW iron dextran, serious or life-threatening reactions are very rare with the use of i.v. irons, and they can be used safely, albeit not overlooking the need for caution, in the treatment of IDA, including that frequently seen in CKD.



Financial support and sponsorship


Conflicts of interest

P.A.K. has received honoraria for lecturing for Pharmacosmos, Vifor, and Takeda, and for participating in advisory boards for Pharmacosmos and Vifor. S.B. received honoraria for lectures from Pharmacosmos A/S and research funding from Takeda.


Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest


1. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care 2009; 32:1320–1326.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616–1634.
3. Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 2012; 3:177–191.
4. Henry DH. The role of intravenous iron in cancer-related anemia. Oncology (Williston Park) 2006; 20 (8 Suppl 6):21–24.
5. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9:211–222.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., Suppl. 2012; 2:279–335.
7. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13:1545–1553.
8. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999–2010: temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134:1318–1328.
9. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: a comparison of two products. Am J Nephrol 2000; 20:455–462.
10. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743–749.
11. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:1571–1575.
12. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378–382.
13. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41 (5 Suppl):18–26.
14. Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36:88–97.
15▪▪. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314:2062–2068.

The study compared the RR of anaphylaxis in 688 183 iron-naïve Medicare recipients treated with i.v. iron dextran, ferric gluconate, iron sucrose, or ferumoxytol between 2003 and 2013. Using questionable definitions of anaphylaxis, they found that this occurred at a rate of 68/100 000 doses for iron dextran and 24/100 000 with the other three irons.

16▪▪. DeLoughery TG, Auerbach M. Is low-molecular weight iron dextran really the most risky iron? Unconvincing data from an unconvincing study. Am J Hematol 2016; 91:451–452.

A critical review of the study performed by Wang et al.[15▪▪] that highlights several controversial methodological issues.

17. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369:1502–1504.
18. Del VL, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J 2016; 9:260–267.
19. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99:1671–1676.
20. Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 2015; 172:5025–5036.
21. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. Kidney Int 2016; 89:28–39.
22. [Accessed 6 June 2016].
23. CDER Medical Review of Ferric carboxymaltose, Application Number: 203565Orig1s000. 21-7-2013. [Accessed 6 June 2016].
    24. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis 1999; 34 (4 Suppl 2):S47–S52.
    25. Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014; 29:809–822.
    26. Fell LH, Seiler-Mussler S, Sellier AB, et al. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. Nephrol Dial Transplant 2016; doi: 10.1093/ndt/gfw045, [Epub ahead of print].
    27. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother 2007; 41:1476–1480.
    28▪▪. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88:905–914.

    An RCT conducted in 136 NDD-CKD patients with IDA treated with either oral iron or i.v. iron sucrose. The primary outcome measure was rate of loss of glomerular filtration rate over time. The study was halted early by the safety monitoring committee because SAEs (infections and major cardiovascular events) occurred more frequently with i.v. iron sucrose than with oral iron and because of futile results relating to the primary outcome.

    29. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822.
    30. Munoz M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822 (response). [Accessed 6 June 2016].
    31. Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436–2448.
    32. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29:2075–2084.
    33. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002; 57:457–461.
    34▪. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90:12–23.

    A meta-analysis of 103 RCTs, including 10 390 patients, who received i.v. iron or a comparator, placebo, or no iron between 1965 and 2013. It concluded that there was no increased risk of infections or other SAE with the use of i.v. irons compared with these other therapies.

    35▪. Ishida JH, Marafino BJ, McCulloch CE, et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clin J Am Soc Nephrol 2015; 10:1799–1805.

    A large retrospective observational cohort study, including data from 22 820 patients, who were Medicare beneficiaries receiving in-centre haemodialysis and who had been hospitalized for bacterial infection in 2010; 2463 (10.8%) had received i.v. iron in the 14 days preceding their hospitalization. The 30-day mortality and readmission rates for infection were similar in those patients receiving i.v. iron compared with patients not receiving i.v. iron.

    36. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40:90–103.
    37. Bresgen N, Eckl PM. Oxidative stress and the homeodynamics of iron metabolism. Biomolecules 2015; 5:808–847.
    38. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65:2279–2289.
    39. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004; 66:144–156.
    40▪. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in nondialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2015; 31:646–655.

    An RCT conducted in 351 iron-deficient NDD-CKD patients receiving either iron isomaltoside or oral iron. The short-term safety profile of iron isomaltoside was comparable with oral iron in patients with NDD-CKD and renal-related anaemia, but more patients stopped oral therapy because of side-effects.

    41. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis 2016; 9:53–64.
    42. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49:2719–2728.
    43. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28:1793–1803.
    44. Dahlerup J, Jacobsen BA, van der Woude J, et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol 2016; 21:1–7.
    45▪. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 2015; 30:1577–1589.

    An RCT conducted in 351 haemodialysis patients receiving either iron isomaltoside or iron sucrose. The short-term safety profile of both iron preparations was very similar, and irons were well tolerated.

    46. Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78:480–491.
    47. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014; 12:296–300.

    anaphylaxis risk; chronic kidney disease; intravenous iron; iron deficiency anaemia

    Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.